Drug intelligence / Profile preview

ENN0403

Development stage: Phase 2
Lead developer: EnnovaBio
Modality: Small Molecules
Administration: Oral

Overview

ENN0403 is an orally administered small molecule drug under development by EnnovaBio for the treatment of diabetic macular edema (DME) and acute kidney injury (AKI). It is a new molecular entity currently in phase II clinical trials for both indications. The precise mechanism of action has not been disclosed. Clinical studies are ongoing to evaluate its efficacy, safety, pharmacokinetics, and pharmacodynamics in patients at high risk for AKI following cardiac surgery and in subjects with DME[1][2][5][7].

Other names: ENN 0403ENN0403ENN-0403

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)

Beyond the preview

Go deeper on ENN0403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENN0403.

Explore the full profile